gfm-1 Antibody

What is GFM1 and why is it significant in mitochondrial research?

GFM1 (G-Elongation Factor, Mitochondrial 1) is a nuclear-encoded protein that plays a critical role in mitochondrial translation elongation. It functions as a key component of the mitochondrial protein synthesis machinery, facilitating the translocation of the ribosome along mRNA during protein synthesis. GFM1's significance stems from its essential role in maintaining proper mitochondrial function through translation of proteins encoded by mitochondrial DNA.

Mutations in the GFM1 gene have been associated with severe mitochondrial disorders characterized by combined oxidative phosphorylation deficiency, encephalopathy, and multi-systemic disease . Research has demonstrated that pathogenic variants in GFM1 can destabilize protein structure, affecting mitochondrial translation and subsequently impairing energy production in cells . GFM1 antibodies are therefore invaluable tools for studying these mechanisms and their disruption in disease states.

What applications are GFM1 antibodies commonly used for in research?

GFM1 antibodies are employed in several key research applications:

• Western Blotting (WB): To detect and quantify GFM1 protein levels in cell or tissue lysates, especially when evaluating protein expression in patient samples compared to controls .

• Immunohistochemistry (IHC): To visualize the localization and expression patterns of GFM1 in tissue sections, providing insights into tissue-specific expression and potential alterations in disease states .

• Immunofluorescence (IF): For subcellular localization studies to confirm mitochondrial targeting of GFM1 and potential colocalization with other mitochondrial markers .

• Immunoprecipitation (IP): To isolate GFM1 protein complexes for studying interaction partners involved in mitochondrial translation .

• Flow Cytometry (FACS): For quantitative analysis of GFM1 expression in specific cell populations .

Each application requires specific optimization regarding antibody dilution, sample preparation, and detection methods to ensure reliable and reproducible results.

How should GFM1 antibodies be selected for specific experimental needs?

Selection of appropriate GFM1 antibodies depends on several factors that should be carefully considered:

For instance, when studying GFM1 isoforms, selecting antibodies targeting different regions can help distinguish between canonical (751 amino acids) and non-canonical (770 amino acids) isoforms . The search results indicate availability of antibodies targeting various regions including AA 1-158, AA 401-500, AA 482-751, and AA 511-751 , providing flexibility for different experimental needs.

How can GFM1 antibodies be used to investigate mitochondrial translation defects?

GFM1 antibodies serve as powerful tools for investigating mitochondrial translation defects through multiple complementary approaches:

• Protein level assessment: Western blotting with anti-GFM1 antibodies can reveal decreased GFM1 protein levels in patient cells harboring pathogenic mutations. This approach was successfully employed to demonstrate significantly reduced GFM1 protein in patients with mitochondrial disease, as shown in the referenced study where immunoblotting revealed markedly decreased GFM1 levels in patient cell lysates .

• Mitochondrial complex assembly evaluation: GFM1 dysfunction impacts mitochondrial protein synthesis, which can be assessed by analyzing respiratory chain complex formation. Blue native polyacrylamide gel electrophoresis (BN-PAGE) combined with immunodetection using antibodies against OXPHOS components can reveal incomplete assembly or reduced stability of mitochondrial complexes. The research shows patients with GFM1 mutations displayed pathognomonic additional lower molecular weight bands of mitochondrial complex V, indicating assembly defects .

• Functional correlation studies: Researchers can correlate GFM1 protein levels (detected by antibodies) with mitochondrial translation capacity and OXPHOS complex activities. In the reported cases, decreased GFM1 levels corresponded with reduced activities of mitochondrial complexes I and IV, establishing a functional link between GFM1 deficiency and combined OXPHOS deficiency .

For comprehensive assessment, these antibody-based approaches should be combined with techniques like pulse-chase labeling of mitochondrial translation products and oxygen consumption measurements to fully characterize the molecular consequences of GFM1 dysfunction.

What considerations are important when using GFM1 antibodies to study alternative splicing and isoforms?

The investigation of GFM1 isoforms and alternative splicing requires careful experimental design when employing antibodies:

• Isoform-specific detection: GFM1 has multiple isoforms, including the canonical isoform (GFM1-001, ENST00000486715) encoding a 751-amino acid protein and a non-canonical isoform (GFM1-004, ENST00000264263) that includes an additional exon between exons 5 and 6, encoding a 770-amino acid protein . Antibodies targeting regions that differ between isoforms are essential for distinguishing these variants.

• Epitope location considerations: When investigating splicing events, antibody epitope location relative to exon-intron boundaries is critical. For instance, in the case described in the search results, a deep intronic mutation (c.689+908 G>A) activated a cryptic splice site, resulting in an in-frame insertion of 19 amino acids . Detection of this altered protein requires antibodies recognizing regions encompassing or adjacent to the insertion site.

• Validation with molecular techniques: Antibody-based detection of splicing variants should be validated with RNA-level analyses. The study employed RT-PCR to amplify the exon/intron junction of GFM1 exons 5 and 6, revealing an additional amplicon in patient samples that was subsequently sequenced to confirm the 57-nucleotide insertion .

This integrated approach combining antibody-based protein detection with nucleic acid analysis provides the most comprehensive characterization of alternative splicing events affecting GFM1.

How can GFM1 antibodies contribute to understanding the connection between mitochondrial dysfunction and congenital disorders of glycosylation?

GFM1 antibodies offer unique insights into the unexpected connection between mitochondrial translation defects and congenital disorders of glycosylation (CDG):

• Correlation analysis: GFM1 antibodies can be used to quantify protein levels in patient fibroblasts or tissues, which can then be correlated with glycosylation abnormalities detected through carbohydrate deficient transferrin (CDT) testing. The reported cases demonstrated abnormal transferrin glycoforms suggestive of type I CDG alongside GFM1 deficiency, establishing a previously unrecognized connection between these pathways .

• Mechanistic investigation: Immunoprecipitation using GFM1 antibodies followed by interactome analysis can help identify potential interactions between mitochondrial translation machinery and glycosylation pathways. This approach could elucidate how GFM1 deficiency leads to glycosylation abnormalities.

• Tissue-specific expression patterns: Immunohistochemistry with GFM1 antibodies can reveal tissue-specific expression patterns, potentially explaining why certain tissues are more affected in patients with GFM1 mutations who present with both mitochondrial dysfunction and glycosylation abnormalities.

The case described in the search results is particularly significant as it proposes considering mitochondrial disease in the differential diagnosis following abnormal transferrin testing . This finding challenges the conventional diagnostic approach and highlights how antibody-based protein detection contributes to uncovering novel disease connections.

What are the optimal conditions for using GFM1 antibodies in western blotting?

Optimizing western blotting conditions for GFM1 detection requires careful consideration of several parameters:

For optimal results when comparing patient samples with controls, it's advisable to run samples in duplicate and include positive controls (tissues known to express GFM1) and negative controls (when available, GFM1-knockout cells). The referenced study successfully detected GFM1 using anti-GFM1 antibodies from Abcam (ab176786 and ab171945) , demonstrating their effectiveness in western blotting applications.

How should GFM1 antibodies be validated to ensure specificity in experimental applications?

• Peptide competition assays: Pre-incubation of the GFM1 antibody with its specific immunizing peptide/antigen should abolish the signal in your application. Products like the GFM1 recombinant protein antigen (NBP1-83997PEP) are specifically designed for such blocking experiments .

• Knockout/knockdown controls: Testing the antibody in GFM1 knockout or knockdown cells provides the most stringent validation. The absence of signal in these samples confirms specificity.

• Multiple antibody approach: Using different antibodies targeting distinct epitopes of GFM1 should yield consistent results. The search results indicate availability of antibodies targeting various regions (AA 1-158, AA 401-500, AA 482-751, and AA 511-751) , which can be used for cross-validation.

• Immunoprecipitation followed by mass spectrometry: This approach confirms that the antibody is pulling down the intended target protein.

• Correlation between protein and mRNA levels: Correlating protein detection by antibodies with mRNA expression data can provide additional validation.

When reporting results, researchers should include detailed information about the validation methods employed, including catalog numbers, clone identifiers for monoclonal antibodies, and specific experimental conditions used for validation. This transparency enhances reproducibility and confidence in the findings.

What approaches can be used to optimize immunohistochemistry protocols for GFM1 detection in tissue samples?

Optimizing immunohistochemistry (IHC) for GFM1 detection requires systematic evaluation of multiple parameters:

• Fixation optimization:

  • Evaluate different fixatives (4% paraformaldehyde, formalin, methanol)

  • Determine optimal fixation duration (typically 24-48 hours)

  • Consider the impact of fixation on epitope accessibility

• Antigen retrieval methods:

  • Heat-induced epitope retrieval (HIER) using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Enzymatic retrieval using proteinase K or trypsin

  • Test different retrieval durations (10-30 minutes)

• Blocking optimization:

  • Evaluate different blocking solutions (5-10% normal serum, protein block, commercial blocking reagents)

  • Determine optimal blocking duration (30-60 minutes)

• Antibody optimization:

  • Perform titration experiments with serial dilutions (1:100, 1:200, 1:500, 1:1000)

  • Compare different GFM1 antibodies targeting various epitopes

  • Evaluate incubation conditions (overnight at 4°C vs. 1-2 hours at room temperature)

• Detection system selection:

  • Polymer-based detection systems typically offer higher sensitivity

  • Tyramide signal amplification for low-abundance targets

  • Chromogenic vs. fluorescent detection based on experimental needs

• Controls:

  • Positive control tissues with known GFM1 expression

  • Negative controls (primary antibody omission, isotype controls)

  • Peptide competition controls using recombinant GFM1 protein antigen

A systematic approach would involve creating a test matrix varying these parameters to identify optimal conditions for specific tissue types. For tissues with high autofluorescence, chromogenic detection may be preferable, while fluorescent detection offers advantages for co-localization studies with other mitochondrial markers.

How should researchers interpret discrepancies between GFM1 protein levels detected by antibodies and mRNA expression?

Discrepancies between GFM1 protein and mRNA levels can provide valuable insights into post-transcriptional regulation but require careful interpretation:

• Post-transcriptional mechanisms: Such discrepancies often indicate post-transcriptional regulatory mechanisms. For GFM1, the search results describe a case where an intronic mutation (c.689+908 G>A) activated a cryptic splice site, resulting in an altered protein despite normal transcription initiation . This illustrates how protein-level analysis with antibodies can reveal alterations not evident from standard mRNA quantification.

• Protein stability assessment: Lower protein levels despite normal mRNA expression may indicate reduced protein stability. The study revealed that GFM1 mutations can lead to protein instability, as demonstrated by significantly decreased GFM1 protein levels detected by immunoblotting . In such cases, cycloheximide chase experiments can help determine if accelerated protein degradation is responsible.

• Isoform-specific effects: Discrepancies may reflect shifts in isoform expression. The referenced research identified a mutation inducing expression of the non-canonical GFM1-004 isoform rather than the canonical GFM1-001 . Depending on the antibody epitope, this shift might not be equally detected at protein and mRNA levels.

• Technical considerations: Before concluding biological significance, technical factors should be ruled out:

  • Antibody specificity issues

  • Different sensitivities of protein and mRNA detection methods

  • Post-translational modifications affecting antibody recognition

When discrepancies are observed, complementary approaches such as polysome profiling, ribosome footprinting, or protein degradation assays can provide mechanistic insights into the underlying causes of differential regulation.

What are common pitfalls in using GFM1 antibodies for studying patient samples with potential mutations?

Researchers studying patient samples with potential GFM1 mutations should be aware of several pitfalls:

• Epitope alterations: Mutations may alter the epitope recognized by the antibody, leading to false-negative results. Using multiple antibodies targeting different regions of GFM1 can mitigate this risk. The search results indicate availability of antibodies targeting various regions (AA 1-158, AA 401-500, AA 482-751, and AA 511-751) , providing options for comprehensive analysis.

• Altered protein migration: Mutations causing insertions, deletions, or post-translational modifications may alter the migration pattern of GFM1 in electrophoresis. The study described a mutation resulting in a 19-amino-acid insertion , which would change the protein's molecular weight.

• Expression variability in different tissues: GFM1 expression varies across tissues, and mutations may have tissue-specific effects. Selecting appropriate control tissues is crucial for meaningful comparisons.

• Isoform complexity: As demonstrated in the research, GFM1 has multiple isoforms, and mutations can affect isoform expression patterns . Antibodies may have different affinities for distinct isoforms.

• Secondary effects on post-translational modifications: Mutations can affect post-translational modifications indirectly, potentially altering antibody recognition.

To address these challenges, researchers should:

• Use multiple antibodies targeting different epitopes

• Include appropriate positive and negative controls

• Correlate antibody-based detection with genetic and functional data

• Consider the specific mutation's location relative to the antibody epitope

• Validate findings with complementary techniques (e.g., mass spectrometry)

How can GFM1 antibodies be effectively used in multiplexed assays to study mitochondrial translation in the context of other mitochondrial processes?

Multiplexed assays using GFM1 antibodies alongside markers for other mitochondrial processes provide comprehensive insights into mitochondrial dysfunction:

• Co-immunofluorescence approaches:

  • GFM1 antibodies can be combined with antibodies against other mitochondrial translation factors (TUFM, TSFM) to assess the entire translation machinery

  • Multiplex with OXPHOS subunit antibodies to correlate translation defects with complex assembly

  • Include markers for mitochondrial dynamics (DRP1, MFN2) or mitophagy (PINK1, Parkin) to assess secondary effects

• Multiparameter flow cytometry:

  • Combine GFM1 antibodies with mitochondrial membrane potential dyes (TMRM, JC-1)

  • Include ROS indicators (MitoSOX, CellROX) to assess oxidative stress

  • Measure mitochondrial mass (MitoTracker Green) simultaneously

• Multiplex western blotting:

  • The study successfully employed total OXPHOS human WB antibody cocktail (Abcam, ab110411) alongside GFM1 antibodies

  • This approach allows simultaneous assessment of multiple OXPHOS complexes

  • Different fluorophore-conjugated secondary antibodies enable detection of multiple targets on a single membrane

• Tissue microarray analysis:

  • GFM1 antibodies can be used in multiplexed IHC or immunofluorescence on tissue microarrays

  • This enables high-throughput assessment of GFM1 expression patterns across multiple tissues or patient samples

  • Co-staining with cell type-specific markers can reveal cell type-specific vulnerabilities

For optimal results, antibody compatibility must be carefully assessed, considering species of origin, isotypes, and detection systems. Additionally, appropriate controls for antibody cross-reactivity and spectral overlap (in fluorescence-based approaches) are essential for reliable interpretation of multiplexed data.

How can GFM1 antibodies contribute to understanding the role of mitochondrial translation in neurodegenerative diseases?

GFM1 antibodies offer valuable tools for investigating the emerging connection between mitochondrial translation defects and neurodegenerative pathology:

• Comparative expression analysis: GFM1 antibodies can be used to compare protein levels in brain tissue from neurodegenerative disease models or patient samples versus controls. This approach could reveal whether mitochondrial translation deficiencies contribute to diseases like Alzheimer's, Parkinson's, or ALS.

• Co-localization with pathological markers: Dual immunofluorescence combining GFM1 antibodies with markers of pathological protein aggregates (β-amyloid, tau, α-synuclein) can reveal spatial relationships between mitochondrial translation defects and hallmark pathologies of neurodegenerative diseases.

• Temporal analysis in disease progression: By analyzing GFM1 expression and localization at different disease stages in animal models, researchers can determine whether mitochondrial translation defects precede or follow other pathological changes.

The clinical presentation of patients with GFM1 mutations includes neurological symptoms and encephalopathy , suggesting that neurons are particularly vulnerable to GFM1 dysfunction. This clinical observation provides a foundation for investigating GFM1's role in more common neurodegenerative conditions where mitochondrial dysfunction is implicated.

What considerations are important when using GFM1 antibodies for high-content screening approaches?

High-content screening with GFM1 antibodies requires careful optimization for reliable, quantitative results:

• Assay development considerations:

  • Cell type selection: Choose cell types relevant to mitochondrial disease (neurons, myocytes, hepatocytes)

  • Fixation and permeabilization optimization: Test multiple protocols to maximize signal-to-noise ratio

  • Antibody dilution optimization: Perform titration experiments to identify conditions providing linear signal response

  • Counter-stains: Include nuclear dyes (DAPI, Hoechst) and mitochondrial markers (MitoTracker, TOMM20)

• Technical parameters for imaging:

  • Resolution requirements: Mitochondrial networks require higher resolution than whole-cell assays

  • Dynamic range: Ensure detection system can accommodate variable expression levels

  • Exposure settings: Standardize exposure times to enable quantitative comparisons

  • Z-stack acquisition: Consider 3D image acquisition to capture the full mitochondrial network

• Analysis parameters:

  • Segmentation approach: Develop algorithms to identify mitochondrial regions accurately

  • Feature extraction: Define relevant parameters (intensity, texture, colocalization)

  • Machine learning integration: Consider supervised learning approaches for complex pattern recognition

  • Normalization strategy: Account for cell-to-cell variability in mitochondrial content

• Quality control measures:

  • Positive controls: Include cells with known GFM1 expression patterns

  • Negative controls: Primary antibody omission and, when available, GFM1-depleted cells

  • Technical replicates: Multiple fields per well to account for intra-well variability

  • Biological replicates: Independent experiments to ensure reproducibility

High-content screening with GFM1 antibodies could be particularly valuable for drug discovery efforts targeting mitochondrial translation, allowing researchers to identify compounds that modulate GFM1 expression or function in a physiologically relevant context.